Altria Group
Sells Marlboro cigarettes, oral tobacco, nicotine pouches and NJOY e-vapor products.
Something off on this page? Send us feedback.
Profile
Sells Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal moist smokeless tobacco, on! nicotine pouches, and NJOY e-vapor products, primarily in the United States. Pricing and brand scale support the cigarette franchise as volumes decline, while FDA oversight, state settlement payments, and NJOY patent restrictions shape the business.
Owns U.S. nicotine businesses spanning Marlboro cigarettes, Black & Mild machine-made cigars, Copenhagen and Skoal moist smokeless tobacco, on! oral nicotine pouches, and NJOY e-vapor products. Marlboro remains the country’s largest-selling cigarette brand and is sold principally through wholesalers and large retail chains.
Uses pricing to offset declining cigarette shipments while expanding on! and on! PLUS. NJOY ACE, its principal e-vapor product, is barred from U.S. importation and sale under an International Trade Commission patent order. Equity investments in AB InBev and Cronos sit outside the core operating portfolio.
Generates substantially all revenue from U.S. customers. FDA rules govern product authorization and marketing; state settlement payments and tobacco litigation remain continuing obligations.
Company facts
Categories
Key statistics
Year to date +19.8% · Average volume (30d) 9.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 11, 2026 | Barclays | Reiterate | Underweight | $64 | $58 |
| Jul 21, 2026 | BTIG | Initiate | Neutral | ||
| Jul 7, 2026 | UBS | Reiterate | Buy | $76 | $79 |
| May 15, 2026 | Barclays | Reiterate | Underweight | $63 | $64 |
| May 4, 2026 | Deutsche Bank | Target | $60 | $66 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.50 | $1.48 | −1.3% | $5.35B | $5.36B | +0.2% | −9.32% |
| Apr 30, 2026Q1 FY26 | $1.25 | $1.32 | +5.6% | $4.58B | $4.76B | +3.9% | +2.62% |
| Jan 29, 2026Q4 FY25 | $1.32 | $1.30 | −1.5% | $5.03B | $5.08B | +0.9% | +3.73% |
| Oct 30, 2025Q3 FY25 | $1.44 | $1.45 | +0.7% | $5.29B | $5.25B | −0.8% | −1.31% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.52B | $5.29B | $5.25B | $5.08B | $5.43B | $6.11B | |
| Gross profit | $3.25B | $3.85B | $3.81B | $3.63B | $3.51B | $4.58B | |
| Operating income | $2.66B | $3.23B | $3.23B | $2.91B | $2.96B | $3.14B | |
| Net income | $1.08B | $2.38B | $2.38B | $1.12B | $2.18B | $2.30B | |
| Diluted EPS | $0.63 | $1.41 | $1.41 | $0.66 | $1.30 | $1.37 | |
| Gross margin | 71.9% | 72.8% | 72.6% | 71.5% | 64.6% | 74.9% | |
| Operating margin | 58.9% | 61.1% | 61.6% | 57.3% | 54.5% | 51.3% |
Fiscal years (4-quarter sums)FY21 $21.11B · FY22 $20.69B · FY23 $20.50B · FY24 $20.44B · FY25 $20.14B
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $2.37B · Total debt $24.58B · Total assets $33.37B · Shareholders' equity −$2.67B
Dividends
Raised for 17 straight years — most recently to $1.06 from $1.02 in Sep 2025. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 15, 2026 | Jun 15 | Jul 10 | $1.06 | |
| Mar 25, 2026 | Mar 25 | Apr 30 | $1.06 | |
| Dec 26, 2025 | Dec 26 | Jan 9 | $1.06 | |
| Sep 15, 2025 | Sep 15 | Oct 10 | $1.06 | raised from $1.02 |
| Jun 16, 2025 | Jun 16 | Jul 10 | $1.02 | |
| Mar 25, 2025 | Mar 25 | Apr 30 | $1.02 | |
| Dec 26, 2024 | Dec 26 | Jan 10 | $1.02 | |
| Sep 16, 2024 | Sep 16 | Oct 10 | $1.02 | raised from $0.98 |
Ownership
Shares outstanding 1.67B · Float 1.67B · 99.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 126.07M | 7.55% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 109.03M | 6.53% | 13F | Aug 13, 2026 |
| State Street Corp | 70.19M | 4.20% | 13F | Aug 7, 2026 |
| Sixth Street Partners Management Company, L.P. | 59.12M | 3.54% | 13F | Aug 14, 2026 |
| Charles Schwab Investment Management Inc | 59.12M | 3.54% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 26, 2026 | Ellen R. Strahlman | director | −2,000 | $72.56 |
| May 26, 2026 | Ennis Debra J. Kelly | director | −5,790 | $72.25 |
| Mar 5, 2026 | Charles N. Whitaker | officer: SVP, Chief HR Off. & CCO | −27,908 | $67.57 |
Peers
- British American Tobacco (ADR)
Broadest US rival across cigarettes, e-vapor, oral pouches, and moist snuff.
- Philip Morris International
Smoke-free rival: Zyn dominates US oral pouches, IQOS re-enters US market.
- Turning Point Brands
Value smokeless rival; FRE/ALP pouches growing fast vs on! in the US market.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Altria Group | $68.70 | +0.09% | $114.63B | 14.5 | 11.9 | 5.2 | +1.3% |
| British American Tobacco (ADR) | $56.13 | +0.02% | $121.07B | 13.9 | — | 3.5 | −0.1% |
| Philip Morris International | $191.85 | −0.01% | $299.08B | 27.6 | 22.0 | 7.0 | +10.4% |
| Turning Point Brands | $83.93 | +0.04% | $1.63B | 36.0 | 77.1 | 3.2 | +22.6% |
| Median | 27.6 | 49.6 | 3.5 | +10.4% |